维康药业
(300878)
| 流通市值：40.40亿 | | | 总市值：40.58亿 |
| 流通股本：1.44亿 | | | 总股本：1.45亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 178,344,442.66 | 126,158,518.77 | 69,661,950.22 | 225,272,638.73 |
| 营业收入 | 178,344,442.66 | 126,158,518.77 | 69,661,950.22 | 225,272,638.73 |
| 二、营业总成本 | 199,655,947.94 | 141,312,717.22 | 59,200,096.66 | 324,809,022.52 |
| 营业成本 | 108,281,104.05 | 75,398,450.21 | 28,213,495.11 | 155,292,116.51 |
| 税金及附加 | 5,256,003.99 | 4,656,341.58 | 2,176,660.68 | 7,597,232.65 |
| 销售费用 | 46,987,688.62 | 35,065,507.94 | 16,691,871.31 | 106,894,703.46 |
| 管理费用 | 30,596,126.27 | 19,971,966.89 | 9,541,350.85 | 40,713,417.63 |
| 研发费用 | 5,182,030.77 | 4,275,599.63 | 2,070,853.96 | 9,371,333.13 |
| 财务费用 | 3,352,994.24 | 1,944,850.97 | 505,864.75 | 4,940,219.14 |
| 其中:利息费用 | 4,697,218.36 | 3,229,119.08 | 5,659,028.07 | 6,273,431.92 |
| 其中:利息收入 | 1,448,190.92 | 1,297,967.08 | 1,108,946.45 | 1,356,985.87 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 117,267.99 | 117,267.99 | - | -12,478,791.23 |
| 加:投资收益 | -150,313.1 | -150,313.1 | 263,572.05 | - |
| 资产处置收益 | -4,360,502.56 | -4,360,502.56 | - | -992,596.01 |
| 资产减值损失(新) | -4,194,036.75 | -2,958,036.01 | -502,303.13 | -95,621,581.13 |
| 信用减值损失(新) | 5,342,238.03 | -609,845.12 | -2,738,495.73 | -1,914,089.44 |
| 其他收益 | 8,961,875.82 | 6,348,660.97 | 1,954,781.05 | 9,000,017.97 |
| 四、营业利润 | -15,594,975.85 | -16,766,966.28 | 9,439,407.8 | -201,543,423.63 |
| 加:营业外收入 | 46,813.89 | 27,156.12 | 16,123.75 | 965,333.41 |
| 减:营业外支出 | 3,958,997.35 | 3,750,882.77 | 3,735,042.68 | 7,897,021.58 |
| 五、利润总额 | -19,507,159.31 | -20,490,692.93 | 5,720,488.87 | -208,475,111.8 |
| 减:所得税费用 | 3,308,817.52 | 1,719,165.82 | 3,877,323.87 | 21,256,694.67 |
| 六、净利润 | -22,815,976.83 | -22,209,858.75 | 1,843,165 | -229,731,806.47 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -22,815,976.83 | -22,209,858.75 | 1,843,165 | -229,731,806.47 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -23,077,914.83 | -22,255,603.93 | 1,743,206.76 | -227,341,721.82 |
| 少数股东损益 | 261,938 | 45,745.18 | 99,958.24 | -2,390,084.65 |
| 扣除非经常损益后的净利润 | -23,135,081.31 | -20,120,582.37 | 3,325,462.37 | -214,567,929.48 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.16 | -0.15 | 0.01 | -1.57 |
| (二)稀释每股收益 | -0.16 | -0.15 | 0.01 | -1.57 |
| 九、综合收益总额 | -22,815,976.83 | -22,209,858.75 | 1,843,165 | -229,731,806.47 |
| 归属于母公司股东的综合收益总额 | -23,077,914.83 | -22,255,603.93 | 1,743,206.76 | -227,341,721.82 |
| 归属于少数股东的综合收益总额 | 261,938 | 45,745.18 | 99,958.24 | -2,390,084.65 |
| 公告日期 | 2026-10-30 | 2026-08-29 | 2026-04-29 | 2026-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |